Lysogene’s Board of Directors is composed of accomplished leaders from the healthcare industry who bring their expertise in science, drug development, commercialization and strategy to developing and expanding our gene therapy programs.
Ms. Karen Pignet-Aiach is Chair of Lysogene’s Board of Directors.
Founder and CEO of Lysogene, Ms. Karen Pignet-Aiach is also the mother of a child with MPS IIIA. She has a strong business background starting her career with Arthur Andersen specializing in audit and transaction services. Her entrepreneurial experience includes founding and running a financial business consultancy. From 2008 to 2009, Ms. Karen Pignet-Aiach served as a Member of the Pediatric Committee at the European Medicines Agency (EMA), established in accordance with the European Pediatric Regulation, as a patient representative. In 2008, she also served on the French Ethical Review Board CCPPRB at Ambroise Paré Hospital. Ms.Karen Pignet-Aiach has been involved with several not-for-profit organizations engaged in advocacy and research in the field of rare diseases such as Alliance Sanfilippo and Eurordis, where she served on the board as treasurer from 2010 to 2011. She is a founding executive member of the International Rare Diseases Research Consortium (IRDiRC).
Ms. Karen Pignet-Aiach graduated from the ESSEC Business School and majored in Economics from Institut d’Études Européennes of University Paris 8.
Dr. Mathieu Simon is a non-Executive, independent member of Lysogene’s Board of Directors.
A graduate in internal medicine from the Faculty of Medicine of Paris VII, Dr. Simon is Senior Strategic Advisor at Messier Maris & Associés, an international investment bank. He is also an independent Director of Vaximm AG, LNC SA, member of the Supervisory Board of Affimed and non-executive member of Idorsia Board of Directors. Moreover, Dr. Simon is an advisor to the European Commission - Research and Innovation. He previously held positions of Executive Vice President, Chief Operating Officer of Cellectis, CEO of Cellectis Therapeutics and CEO of Ectycell; Senior Vice President and Head of Global Pharmaceutical Operations at Pierre Fabre SA, as well as general management and senior corporate roles at Wyeth Pharmaceuticals. He was also Chairman of the Board of Directors of Cellartis AB.
Ms Annette Clancy is a non-Executive, independent member of Lysogene’s Board of Directors.
Ms Annette Clancy has over 15 years’ experience in business development having served as Head of Global Transactions and Alliance Management at GlaxoSmithKline (GSK) up until 2008 where she was responsible for executing innovative deals ranging from early drug discovery partnerships, to global commercial alliances and mergers and acquisitions. Prior to her role in business development, Ms. Annette Clancy held a number of positions in clinical research, R&D project management and commercialization within GSK, developing a broad range of commercial and business expertise. Ms. Annette Clancy is currently Senior European Advisor to the life science team of Frazier Healthcare. In addition to this role, Ms. Annette Clancy has held a number of non-executive board positions on private and public European biotech companies and she currently serves as Chair of the Board at Genable Technologies Ltd (Ireland) and Obseva Ltd (Switzerland) and is a Non-Executive Director on the Board of SOBI Inc (Sweden).
Ms. Annette Clancy has a B.Sc. (Hons) Pharmacology from Bath University and is based in London, UK.
Dr. Philippe Goupit is a non-Executive, independent member of Lysogene’s Board of Directors.
Dr. Philippe Goupit graduated from the Paris School of Pharmacy and held several key positions in sales, marketing and regulatory affairs at Servier and then at Pasteur in the vaccines sector. Subsequently, he was appointed VP, Mergers & Acquisitions at Sanofi, a global leader in the healthcare sector. He was also Head of Investor Relations at the Sanofi group for several years. Dr. Philippe Goupit currently sits on the Board of Directors of MedDay Pharmaceuticals, a pioneer in developing therapies for central nervous system disorders.
Mr. David Schilansky is a non-Executive, independent member of Lysogene’s Board of Directors.
Mr. David Schilansky, currently Deputy CEO and Chief Operating Officer of DBV Technologies (Euronext: DBV; NASDAQ: DBVT), has 20 years of leadership experience in the field of biotechnology and finance. DBV Technologies is a late clinical-stage specialty biopharmaceutical company, for which Mr. David Schilansky oversees the company’s strategic implementation. He was appointed to this role in January 2015 after serving as the Chief Financial Officer from 2011. He is a member of DBV Technologies’ Executive Committee. Previously, Mr. David Schilansky held various senior positions at Ipsen Pharma, including Interim Chief Financial Officer. Earlier in his career, he worked at Thomson Inc. (now Technicolor S.A.) as co-head of investor relations and at Warburg Dillon Read (now UBS) in mergers and acquisitions.
Mr. David Schilansky received a master’s degree from the University of Paris Dauphine and a post-graduate degree from the Imperial College London.
Dr. Peter Lichtlen is a non-Executive, independent member of Lysogene's Board of Directors.
Dr. Peter Lichtlen was Chief Medical Officer at Sucampo Pharmaceuticals Inc. until the company’s acquisition by Mallinckrodt Pharmaceuticals earlier this year and has 18 years of leadership experience in the field of biotechnology.
Prior to joining Sucampo, Dr. Lichtlen was at ESBATech AG (acquired by Alcon/Novartis in 2009), which he joined in 2000. At ESBATech, Dr. Peter Lichtlen served as Medical Director/Head Clinical Research and Development and was a member of its senior management team, from 2004 to 2010. Dr. Peter Lichtlen also co-founded Numab AG, a Swiss biotechnology company that develops antibody-based therapeutics, where he remains a member of the Board of Directors and Chief Medical Officer. Dr. Peter Lichtlen also currently serves on the scientific advisory board of Apidel SA, a drug delivery company.
Dr. Peter Lichtlen is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of several patents.
Dr. Peter Lichtlen earned a Bachelor’s Degree in business administration, and doctorate degrees in medicine and molecular biology at the University of Zurich.